A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton's tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B cell malignancies Meeting Abstract
| Authors: | Danilov, A.; Tees, M. T.; Patel, K.; Wierda, W. G.; Patel, M.; Flinn, I. W.; Latif, T.; Ai, W. Y.; Thompson, M. C.; Wang, M. L.; Sun, C.; Stephens, D. M.; Thirman, M. J.; Gessner, M.; Wolff, J.; Schwab, A.; Tan, M.; Chan, D.; Meredith, E.; Wiestner, A. |
| Abstract Title: | A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton's tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B cell malignancies |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4463 |
| Language: | English |
| ACCESSION: | WOS:001159740307209 |
| DOI: | 10.1182/blood-2023-179872 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
